Geron (NASDAQ:GERN) Trading Down 3% - What's Next?

Geron Co. (NASDAQ:GERN - Get Free Report) shares traded down 3% during trading on Monday . The stock traded as low as $1.77 and last traded at $1.77. 1,451,958 shares traded hands during trading, a decline of 90% from the average session volume of 14,617,280 shares. The stock had previously closed at $1.82.

Wall Street Analysts Forecast Growth

A number of analysts have commented on GERN shares. Barclays reaffirmed an "overweight" rating and set a $4.00 price target (down previously from $9.00) on shares of Geron in a research report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and issued a $5.00 price objective on shares of Geron in a research note on Wednesday, March 12th. B. Riley cut shares of Geron from a "buy" rating to a "neutral" rating and dropped their price target for the company from $3.50 to $2.00 in a research report on Thursday, February 27th. Stifel Nicolaus cut their price objective on shares of Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of Geron in a report on Wednesday, March 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Geron presently has a consensus rating of "Moderate Buy" and an average target price of $5.75.

Geron Trading Down 1.5 %

The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The company has a 50-day moving average price of $2.32 and a two-hundred day moving average price of $3.41. The stock has a market cap of $1.03 billion, a P/E ratio of -5.05 and a beta of 0.53.

Remove Ads

Geron (NASDAQ:GERN - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million during the quarter, compared to analyst estimates of $45.29 million. On average, research analysts expect that Geron Co. will post -0.25 EPS for the current fiscal year.

Institutional Trading of Geron

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Alternative Investment Advisors LLC. increased its position in shares of Geron by 13.3% in the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company's stock valued at $101,000 after acquiring an additional 2,612 shares during the period. Rovin Capital UT ADV grew its stake in Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock valued at $61,000 after purchasing an additional 3,660 shares during the last quarter. Xponance Inc. increased its holdings in shares of Geron by 12.9% in the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock valued at $150,000 after purchasing an additional 4,829 shares during the period. KBC Group NV raised its stake in shares of Geron by 45.1% in the fourth quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company's stock worth $86,000 after purchasing an additional 7,592 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Geron during the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 73.71% of the company's stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.